NEORX CORP
10-Q, EX-27, 2000-07-25
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NEORX CORP, 10-Q, 2000-07-25
Next: MORGAN STANLEY DEAN WITTER CAPITAL I INC, 8-K, 2000-07-25



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM 6/30/2000
10(Q) AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                           3,798
<SECURITIES>                                    27,174
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                31,632
<PP&E>                                           8,481
<DEPRECIATION>                                   7,576
<TOTAL-ASSETS>                                  32,957
<CURRENT-LIABILITIES>                            1,605
<BONDS>                                              0
                                0
                                          4
<COMMON>                                           471
<OTHER-SE>                                      30,877
<TOTAL-LIABILITY-AND-EQUITY>                    32,957
<SALES>                                              0
<TOTAL-REVENUES>                                   904
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                11,153
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  46
<INCOME-PRETAX>                                (6,221)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (6,221)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (6,221)
<EPS-BASIC>                                      (.29)
<EPS-DILUTED>                                    (.29)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission